Trabedersen

Trabedersen (OT-101) is an investigational agent whose form is not stated in the registry developed by Oncotelic. The sponsor describes its target as TGF-beta2, which OnCo does not yet have a target page for. The sponsor states: An antisense oligodeoxynucleotide complementary to TGF-beta2 mRNA; by suppressing TGF-beta2, which cancers overexpress to cloak themselves from the immune system, it is intended to let innate or therapeutic immunity attack and eliminate the tumour. ClinicalTrials.gov describes the intervention as: OT-101: antisense oligodeoxynucleotide complementary to the messenger ribonucleic acid (mRNA) of the human TGF-β2 gene. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06079346 (A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer), in pancreatic ductal adenocarcinoma. The largest, NCT06079346, plans to enrol 455 participants with primary completion expected 2026-06-01. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.